Melanoma preferentially expressed antigen (PRAME) is highly expressed in patients with liver cancer, and studies have found that Evo can inhibit tumor metastasis by inhibiting the expression of PRAME (Zhu et al., 2019). Here, PRAME is linked to neoplasm.